Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.
TABLE OF CONTENTS
4 Product Profiles
4 Provenge : Prostate cancer
LIST OF FIGURES
7 Figure 1: Provenge for prostate cancer – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Provenge for prostate cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Provenge for prostate cancer
11 Figure 4: Provenge sales for prostate cancer in the US, 2017–26
LIST OF TABLES
4 Table 1: Provenge drug profile
6 Table 2: Provenge pivotal Phase III data in prostate cancer
11 Table 3: Provenge sales for prostate cancer in the US ($m), 2017–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726